These two new patents further strengthen the portfolio of 22 patents covering all the aspects of the JAZZ platform. It is the result of an extremely proactive and rigorous policy that is one of the strategic keys to commercial development and value creation.
Régis Le Couedic, Implanet’s product development and manufacturing director, said, “These two new U.S. patents expand our protection on this highly competitive market. Intellectual property is essential to Implanet’s formula, we meticulously manage our portfolio. Clinical results support the fact that we possess the band market’s most advanced implants and instrumentation. We will continue to expand the scope of protection covering our JAZZ platform and future innovations.”
Ludovic Lastennet, CEO of Implanet, added, “Obtaining these patents is an integral part of our value-creation strategy, we aim to put solid barriers in place in an addressable spine market estimated at $2.1 billion. The systematic growth of our IP protection enables us to reinforce our current commercial partnerships and look towards future strategic alliances.”
Founded in 2007, Implanet manufactures orthopedic implants. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the U.S. Food and Drug Administration and the CE mark. Implanet employs 48 staff and recorded 2016 sales of 7.8 million euros. Based near Bordeaux in France, Implanet established a U.S. subsidiary in Boston, Mass, in 2013. Implanet is listed on Euronext Growth market in Paris, France.